Omarigliptin

Clinical data
Other names	MK-3102
Routes of administration	Oral
ATC code	None
Legal status
Legal status	Developing
Identifiers
IUPAC name (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine
CAS Number	1226781-44-7
PubChem CID	46209133
ChemSpider	28424182
UNII	CVP59Q4JE1
KEGG	D10317
ChEMBL	ChEMBL2105762
CompTox Dashboard (EPA)	DTXSID70153678
ECHA InfoCard	100.207.924
Chemical and physical data
Formula	C17H20F2N4O3S
Molar mass	398.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)n1cc2c(n1)CN(C2)[C@@H]3C[C@@H]([C@H](OC3)c4cc(ccc4F)F)N
InChI InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1 Key:MKMPWKUAHLTIBJ-ISTRZQFTSA-N

Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co.^[1] It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP),^[2][3][4] which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.

History

Marizev (omarigliptin) 25 mg and 12.5 mg tablets were approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on 28th Sept 2015. Japan was the first country to have approved omarigliptin.^[5] However Merck has announced that the company will not submit marketing application in the US and Europe.^[6]